Announced
Synopsis
Pharmaceutical company ANI Pharmaceuticals agreed to acquire Novitium Pharma, a New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities, for $210m. "Strengthening our well-established Generics business with enhanced development capabilities and increased focus on niche opportunities is a key pillar of ANI’s growth strategy. The acquisition of Novitium aligns with this strategy, adding a best-in-class R&D engine that delivers sustainable growth through new product launches and offering upside through niche 505(b)(2) opportunities," Nikhil Lalwani, ANI Pharmaceuticals President and CEO. On November 10, 2021, FTC approved the deal with conditions.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.